Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

5th International summit on Medical Biology & Bioengineering

Chicago, USA

Urmila M Diwekar

Urmila M Diwekar

Vishwamitra Research Institute, USA

Title: From particulate processes to in vitro fertilization modeling and optimization

Biography

Biography: Urmila M Diwekar

Abstract

In-vitro fertilization (IVF) is a treatment process for infertility by which oocytes or egg cells are fertilized by a sperm outside the body in a laboratory simulating the similar conditions in the body, and then the fertilized eggs are implanted back into the uterus for full term completion of pregnancy. IVF is divided into four stages, namely: Superovulation, egg collection, insemination/fertilization, and embryo transfer. Superovulation is an important step in IVF and involves the production of multiple eggs using drug induced simulation. In normal female body only one egg is ovulated per menstrual cycle, but with the use of fertility drugs and hormones, a number of follicles (eggs) can be produced per cycle. This involves daily injections of drugs/hormones and daily monitoring of number and size of eggs produced. The success of IVF depends on the quality and quantity of eggs produced in the superovulation stage. The drug delivery per day depends upon the distribution of egg size obtained previous day. Hence close monitoring is involved. The cost of drugs and monitoring makes this stage very expensive stage in the IVF cycle. Particulate processes like crystallization are well-understood phenomena which involve models of particle size distribution. In this work, we use the analogy between particulate processes like crystallization to derive customized models for IVF patients. The first two days of follicle distributions for each patient are used to develop the model for the effect of hormones on the size distribution as the treatment progresses. Optimal control theory then is applied to find optimal dosage of hormones for each patient. It has been shown in our theoretical analysis and preliminary clinical trials in India that this approach reduces daily monitoring to a minimum. This approach also reduces the total drugs given to patient significantly with better outcomes of superovulation stage. In future, we will be conducting a large scale clinical trial with this approach in the United States. This new way of modeling biomedical processes with size distribution can be applied to other diseases like Cancer treatment.